Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Condu
Summit Therapeutics' partner Akeso announced that ivonescimab, a bispecific antibody, showed a 27% reduction in death risk and an 8.2-month improvement in median overall survival compared to pembrolizumab in the HARMONi-2 study for PD-L1-positive advanced NSCLC. The trial met its secondary endpoint with a hazard ratio of 0.73. Ivonescimab is approved in China and is being studied in a global Phase III trial (HARMONi-7).
How this was made
The 30-second read
Why it matters
The interim OS results represent a material advancement over pembrolizumab, potentially accelerating regulatory submissions and commercial rollout outside China.
Market read
First‑time disclosure of pivotal trial OS data; likely to move Summit's stock and influence the NSCLC immunotherapy market.
What to watch
Future data on overall survival maturity and comparative safety profile will be critical for broader adoption.
Background
Summit Therapeutics partners with Akeso Inc. to develop ivonescimab, a PD‑1/VEGF bispecific antibody for NSCLC. The data were presented at the IASLC World Conference on Lung Cancer in Seoul.
Ticker impact
Summit Therapeutics (SMMT) announced interim overall survival data from the Phase III HARMONi-2 trial, showing ivonescimab reduced risk of death versus pembrolizumab (HR 0.73, p=0.009).
Potential upside of 10-15% over the next weeks if data drives investor optimism.
First disclosure of statistically significant OS benefit in a pivotal trial; market typically reacts strongly to such data.
Market effects
Strengthens the bispecific antibody segment and may pressure competitors in the NSCLC immuno‑oncology space.
Highlights Chinese market data; could influence Asian biotech investors.
Adds to global pipeline confidence for bispecific immunotherapies.
Counterpoint
Skeptics may question durability of benefit given limited follow‑up and pending regulatory approvals outside China.
Key entities
- CompanySummit Therapeutics Inc.
US‑listed biotech developing ivonescimab.
- CompanyAkeso Inc.
Partner and developer of ivonescimab, listed in Hong Kong (9926.HK).
